Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1007/s00204-025-04235-5

http://scihub22266oqcxt.onion/10.1007/s00204-025-04235-5
suck pdf from google scholar
41369776!?!41369776

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=41369776&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi

pmid41369776      Arch+Toxicol 2025 ; ? (?): ?
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Mechanism-based new approach methodologies for in vitro detection of chemical-induced liver steatosis #MMPMID41369776
  • Verhoeven A; Sanz-Serrano J; Vinken M
  • Arch Toxicol 2025[Dec]; ? (?): ? PMID41369776show ga
  • Liver steatosis resulting from chemical exposure is a growing clinical concern, pointing to the need for early detection in chemical safety assessments. New approach methodologies (NAMs) based on adverse outcome pathway (AOPs) networks are emerging tools to assess the safety of chemicals as an alternative to animal studies. Amongst others, NAM can include a human-based in vitro system linked to a battery of complementary assays, each measuring an individual key event within the respective AOP network. These AOP-based NAMs allow to acquire mechanistic insight, while facilitating the translation of in vitro data into outcomes relevant to hazard assessment. The current review provides pragmatic guidance for developing NAMs entailing an AOP network-driven in vitro testing platform suitable for steatogenic hazard assessment of chemicals, intended for use in academic, industrial and regulatory settings. In a first part, underlying mechanisms for highly specific key events for liver steatosis are described. In a second part, a workflow is provided for the establishment of NAMs, including the selection of human-based in vitro cell models, functional in vitro assays, reference control chemicals, exposure and treatment conditions. In a third part, future perspectives for AOP-based liver steatosis risk assessment are outlined.
  • ?


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box